<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315052</url>
  </required_header>
  <id_info>
    <org_study_id>Budesonied Trial</org_study_id>
    <nct_id>NCT03315052</nct_id>
  </id_info>
  <brief_title>Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects</brief_title>
  <acronym>BILT</acronym>
  <official_title>Budesonide in Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that budesonide will provide effective hepatic ISP that will replace
      prednisone and allow lower systemic drug levels of FK, thus reducing the steroid- and
      calcineurin-associated complications often observed in the OLT population. This study is
      intended to investigate the therapeutic potential of this ISP combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized, open-label non-inferiority trial to assess the efficacy,
      safety and tolerability of budesonide in combination with low-dose FK and standard-dose MMF
      as post-OLT ISP in comparison to standard ISP (S-ISP). Subjects will include OLT patients age
      18 years and older receiving their first single-organ living- or deceased-donor liver
      transplant. Subjects must have post-operative recovery of graft function and be able to take
      oral medications before beginning treatment according to the study protocol.

      Subjects will be randomized to receive either (1) investigational oral ISP including
      budesonide 9mg by mouth in three daily divided doses, FK with an initial target trough level
      of no greater than 5-6ng/mL, and MMF (I-ISP); or (2) S-ISP including prednisone, calcineurin
      antagonist, and MMF. After randomization, subjects will be followed for a total of 52 weeks
      and assessed for adequacy of graft function, and complications of therapy, particularly ACR
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Comparison of standard immunosuppression to immunosuppression incorporating budesonide in place of prednisone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute cellular rejection (ACR)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of ACR in budesonide treatment arm as compared to standard treatment arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus trough levels</measure>
    <time_frame>12 months</time_frame>
    <description>Cumulative average trough level of tacrolimus in budesonide and standard treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of diabetes in in budesonide and standard treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening kidney function</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of worsening kidney function in budesonide and standard treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyptertension</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of hypertension in in budesonide and standard treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>12 months</time_frame>
    <description>Graft survival in budesonide and standard treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>12 months</time_frame>
    <description>Patient survival in budesonide and standard treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of infection in budesonide and standard treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Cellular Graft Rejection</condition>
  <condition>Liver Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Budesonide treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with budesonide in place of prednisone as part of immunosuppressive regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard immunosuppression arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with standard immunosuppression after liver transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Oral steroid with high first-pass metabolism in liver</description>
    <arm_group_label>Budesonide treatment arm</arm_group_label>
    <other_name>Enterocort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus（FK506）</intervention_name>
    <description>Calcineurin immunosuppressant</description>
    <arm_group_label>Budesonide treatment arm</arm_group_label>
    <arm_group_label>Standard immunosuppression arm</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Immunosupressant</description>
    <arm_group_label>Budesonide treatment arm</arm_group_label>
    <arm_group_label>Standard immunosuppression arm</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Immunosuppresant</description>
    <arm_group_label>Standard immunosuppression arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Adult patients age 18 years or older who undergo initial single-organ
        living- or deceased-donor liver-transplant surgery. Research participants are required to
        have satisfactory post-operative recovery of graft function and no post-operative
        renal-replacement therapy prior to starting medication according to protocol. They must
        also be able to take oral medications.

        Exclusion Criteria: Patients will be excluded from the study if they are: (1) undergoing
        retransplantation; (2) have fulminant hepatic failure as an indication for liver
        transplantation; (3) have surgical complication(s) potentially affecting post-operative
        graft function (i.e., hepatic artery thrombosis); or have delayed initial recovery of graft
        function (primary non-function) requiring non-standard induction therapy. Furthermore,
        patients with a contraindication to budesonide (i.e., hypersensitivity) will not be
        included in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John F Reinus, MD</last_name>
    <phone>1-718-920-7516</phone>
    <email>jreinus@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samuel H Sigal, MD</last_name>
    <phone>1-718-920-7516</phone>
    <email>ssigal@montefiore.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Jönsson G, Aström A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995 Jan;23(1):137-42.</citation>
    <PMID>7720517</PMID>
  </reference>
  <reference>
    <citation>Weber T, Kalbhenn T, Herrmann G, Hanisch E. Local immunosuppression with budesonide after liver transplantation in the rat: a preliminary histomorphological analysis. Transplantation. 1997 Sep 15;64(5):705-8.</citation>
    <PMID>9311706</PMID>
  </reference>
  <reference>
    <citation>Ozcay N, Fryer J, Grant D, Freeman D, Garcia B, Zhong R. Budesonide, a locally acting steroid, prevents graft rejection in a rat model of intestinal transplantation. Transplantation. 1997 May 15;63(9):1220-5.</citation>
    <PMID>9158013</PMID>
  </reference>
  <reference>
    <citation>Bhat M, Ghali P, Wong P, Marcus V, Michel R, Cantarovich M, Metrakos P, Deschenes M. Immunosuppression with budesonide for liver transplant recipients with severe infections. Liver Transpl. 2012 Feb;18(2):262-3. doi: 10.1002/lt.22453.</citation>
    <PMID>22006869</PMID>
  </reference>
  <reference>
    <citation>Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep;9(9):738-46. doi: 10.1093/ecco-jcc/jjv101. Epub 2015 Jun 20.</citation>
    <PMID>26094251</PMID>
  </reference>
  <results_reference>
    <citation>Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Günther R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Färkkilä M, Pröls M, Strassburg CP; European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010 Oct;139(4):1198-206. doi: 10.1053/j.gastro.2010.06.046. Epub 2010 Jun 22.</citation>
    <PMID>20600032</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>John Reinus</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Graft loss</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Infection</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Hypertension</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Annonymous IPD will be shared in the event that the study protocol is approved at other transplanting institutions who then collaborate in this study. IPD will include standard clinical and laboratory data monitored after liver transplantation</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

